Loading
Latest filing published 15 Nov 2017 for Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation).
No signal scores available.
Philippe Perron Savard appears in our data through filings on Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) shares, published by SEDI. Over a trading history stretching from 4 July 2016 to 15 November 2017, the count stands at 2 filings.
On the market, this insider has only ever bought: 1 purchase, €3,295 in total. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2017 alone, the filings show 1 purchase and no sales.
The latest filing, published on 15 November 2017, reports a transaction in Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation). The last purchase on record was published on 15 November 2017, which is 3,265 days ago. Source: insider filings from SEDI. Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations